POSTNEOADJUVANT THERAPY STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for POSTNEOADJUVANT THERAPY STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new POSTNEOADJUVANT THERAPY STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for POSTNEOADJUVANT THERAPY STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy combo shows promise in Hard-to-Treat stomach cancer
Disease control OngoingThis early-stage trial tests whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy can help control advanced gastroesophageal cancer that cannot be surgically removed. The study enrolled 16 participants and aims to see if the combination can make the c…
Matched conditions: POSTNEOADJUVANT THERAPY STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New way to deliver chemo shows promise for stomach cancer patients
Disease control OngoingThis early-phase study tests a chemotherapy drug called paclitaxel, given directly into the abdomen, for people with advanced stomach cancer that has spread to the lining of the belly. The main goal is to find the safest dose and understand side effects. About 27 adults with this…
Matched conditions: POSTNEOADJUVANT THERAPY STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
Experimental combo targets Hard-to-Treat esophageal cancer
Disease control OngoingThis early-stage trial tested a drug called adavosertib together with radiation therapy for people with advanced esophageal or stomach cancer that cannot be surgically removed. The goal was to find the safest dose and see how well the combination works. Only 4 people took part, s…
Matched conditions: POSTNEOADJUVANT THERAPY STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 09, 2026 12:06 UTC